Difference between revisions of "Trimethoprim-Sulfamethoxazole (Bactrim DS)"
m |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Sulfonamide antibiotic, combination of trimethoprim and sulfamethoxazole. Sulfamethoxazole and trimethoprim work synergistically to block two consecutive steps of nucleic acid synthesis in bacteria. Sulfamethoxazole is a competitive inhibitor of para-aminobenzoic acid (PABA) and blocks bacterial synthesis of dihydrofolic acid. Trimethoprim reversibly inhibits dihydrofolate reductase, blocking the production of tetrahydrofolic acid from dihydrofolic acid.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/17377slr057_Bactrim_lbl.pdf Trimethoprim/Sulfamethoxazole (Bactrim DS) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ | + | Class/mechanism: Sulfonamide antibiotic, combination of trimethoprim and sulfamethoxazole. Sulfamethoxazole and trimethoprim work synergistically to block two consecutive steps of nucleic acid synthesis in bacteria. Sulfamethoxazole is a competitive inhibitor of para-aminobenzoic acid (PABA) and blocks bacterial synthesis of dihydrofolic acid. Trimethoprim reversibly inhibits dihydrofolate reductase, blocking the production of tetrahydrofolic acid from dihydrofolic acid.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/17377slr057_Bactrim_lbl.pdf Trimethoprim/Sulfamethoxazole (Bactrim DS) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trimethoprimsulfamethoxazole.pdf Trimethoprim/Sulfamethoxazole (Bactrim DS) package insert (locally hosted backup)]</ref> |
<br>Route: PO, IV | <br>Route: PO, IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Revision as of 00:52, 26 February 2012
General information
Class/mechanism: Sulfonamide antibiotic, combination of trimethoprim and sulfamethoxazole. Sulfamethoxazole and trimethoprim work synergistically to block two consecutive steps of nucleic acid synthesis in bacteria. Sulfamethoxazole is a competitive inhibitor of para-aminobenzoic acid (PABA) and blocks bacterial synthesis of dihydrofolic acid. Trimethoprim reversibly inhibits dihydrofolate reductase, blocking the production of tetrahydrofolic acid from dihydrofolic acid.[1][2]
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].